Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 336-340

  Tanner, Edward J ^a   Chi, Dennis S ^b   Eisenhauer, Eric L ^b   Diaz Montes, Teresa P ^a   Santillan, Antonio ^a   Bristow, Robert E ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Follow up; Ovarian cancer; Recurrence; Surveillance

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARIECTOMY; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 77950187418     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.014     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA. Cancer J. Clin. 59 4 (2009 Jul-Aug) 225-249
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 17 (2003 September 1) 3194-3200
3. Gadducci A., Cosio A., Zola P., Landoni F., Maggino T., and Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int. J. Gynecol. Cancer 17 1 (2007) 21-31
4. Prayer L., Kainz C., Kramer J., Stiglbauer R., Schurawitzki H., Baldt M., et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J. Comput. Assist. Tomogr. 17 4 (1993 Jul-Aug) 626-632
5. Fehm T., Heller F., Kramer S., Jager W., and Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 25 May-Jun 3A (2005) 1551-1554
6. Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J.S., Soletormos G., Torre G.C., et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int. J. Gynecol. Cancer 15 5 (2005) 679-691
7. Parker P.A., Kudelka A., Basen-Engquist K., Kavanagh J., de Moor J., and Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol. Oncol. 100 3 (2006 Mar) 495-500
8. Rustin G.J., and van der Burg M.E. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment bason on conventional clinical indicators (MRCOV05/EORTC 55955 trials). J. Clin. Oncol. 18s (2009) 27
9. Gadducci A., Fuso L., Cosio S., Landoni F., Maggino T., Perotto S., et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int. J. Gynecol. Cancer. 19 3 (2009 Apr) 367-374
10. Segna R.A., Dottino P.R., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 3 (1993 Mar) 434-439
11. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 1 (2000 Jan 1) 144-153
12. Zang R.Y., Zhang Z.Y., Li Z.T., Cai S.M., Tang M.Q., Chen J., et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26 8 (2000 Dec) 798-804
13. Gronlund B., Christensen I.J., Bulow-Lehnsby A.L., Engelholm S.A., Hansen H.H., and Hogdall C. Recurrent epithelial ovarian cancer: validation and improvement of an established prognostic index. Eur. J. Obstet. Gynecol. Reprod. Biol. 123 1 (2005 Nov 1) 98-106
14. Hoskins P., Tu D., James K., Pater J., and Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol. Oncol. 70 2 (1998 Aug) 224-230
15. Cohen Z.R., Suki D., Weinberg J.S., Marmor E., Lang F.F., Gershenson D.M., et al. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J. Neurooncol. 66 3 (2004 Feb) 313-325
16. Cormio G., Rossi C., Cazzolla A., Resta L., Loverro G., Greco P., et al. Distant metastases in ovarian carcinoma. Int. J. Gynecol. Cancer 13 2 (2003 Mar-Apr) 125-129
17. Larson J.E., Podczaski E.S., Manetta A., Whitney C.W., and Mortel R. Bowel obstruction in patients with ovarian carcinoma: analysis of prognostic factors. Gynecol. Oncol. 35 1 (1989 Oct) 61-65
18. Salani R., Santillan A., Zahurak M.L., Giuntoli II R.L., Gardner G.J., Armstrong D.K., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 4 (2007 Feb 15) 685-691
19. Benedetti Panici P., De Vivo A., Bellati F., Manci N., Perniola G., Basile S., et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann. Surg. Oncol. 14 3 (2007 Mar) 1136-1142
20. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 9 (2006 May 1) 1933-1939
21. Chi D.S., Eisenhauer E.L., Zivanovic O., Sonoda Y., Abu-Rustum N.R., Levine D.A., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114 1 (2009) 26-31
22. Silber J.H., Rosenbaum P.R., Polsky D., Ross R.N., Even-Shoshan O., Schwartz J.S., et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?. J. Clin. Oncol. 25 10 (2007 Apr 1) 1169-1175